1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow IC-MPGN: new trials by email Literature Review of IC-MPGN trials Research Report on IC-MPGN
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Pegcetacoplan - C3G, IC-MPGN | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 13 | 2021-09-07 | 2026-04-21 |
Glomerulonephritis, Membranoproliferative (1)
Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Glomerulonephritis (1) · Immune System Diseases (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Nephritis (1) · Urogenital Diseases (1) · Urologic Diseases (1)
pegcetacoplan (1)
Apellis Pharmaceuticals, Inc. (1)
Argentina (1) · Australia (1) · Austria (1) · Brazil (1) · France (1) · Italy (1) · Netherlands (1) · Spain (1) · Switzerland (1) · United Kingdom (1) · United States (1)